Potomac Capital Partners Opens Position in Meru Networks, Inc. (MERU)

Potomac Capital Partners III, L.P. is betting on Meru Networks, Inc. (NASDAQ:MERU). In a recent filing with the Securities and Exchange Commission, Potomac Capital revealed opening a position in Meru Networks. The fund currently holds 1,171,226 shares which account for 5.2% of the company’s common stock. The position is passive by nature, although Potomac Capital does not dismiss the possibility of interfering with Meru Networks management in the future.

Meru Networks, Inc. (MERU)

David E. Shaw and his fund, D E Shaw, are keeping an eye on Meru Networks, Inc. (NASDAQ:MERU), as they currently hold 1.4 million shares reportedly worth a little over $4.6 million. D E Shaw has not made any changes to its position during the third quarter of 2013. Mark N. Diker has increased his fund’s holding of the stock by 28% during Q3. Diker Management has reported in their latest 13F filing the ownership of 1.16 million shares valued at $3.8 million. Richard Driehaus has, on the other hand, been limiting his fund’s exposure to Meru Networks. During Q3, Driehaus Capital has decreased its investment to 729,288 shares valued at $2.4 million.

Meru Networks, Inc. (NASDAQ:MERU) provides wireless communication services. In 2013, the stock had advanced 162% to an April high of $6.96. It later fell considerably and has been trending sideways since August, in the range of $3-$4 per share. With a current share price of $3.52, the company has a market cap of $79.7 million. The stock has a beta of 1.54 and does not pay a dividend.

On November 1st, Meru Networks released its quarterly financial report. For the three months ended September 30, 2013, the company reported revenues of $19.6 million and a loss per share of $0.16. Analysts expect the company to post revenues of $27 million and a loss of $0.06 per share at the end of the current quarter.

Disclosure: none

Recommended reading:

Bison Capital Holding Opens Position In AirMedia Group Inc (ADR) (AMCN)

Hedge Fund News: Kyle Bass, Bill Ackman & George Soros

Roumell Asset Management Nominates Candidates for Transcept Pharmaceuticals Inc (TSPT)’s Board

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!